| Triple-negative breast cancer: understanding Wnt signaling in drug resistance P Merikhian, MR Eisavand, L Farahmand Cancer cell international 21 (1), 419, 2021 | 55 | 2021 |
| MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer P Merikhian, R Ghadirian, L Farahmand, S Mansouri, K Majidzadeh-A Expert Review of Anticancer Therapy 17 (7), 607-613, 2017 | 43 | 2017 |
| Significant role of MUC1 in development of resistance to currently existing anti-cancer therapeutic agents L Farahmand, P Merikhian, N Jalili, B Darvishi, K Majidzadeh-A Current Cancer Drug Targets 18 (8), 737-748, 2018 | 39 | 2018 |
| Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER S Moradi-Kalbolandi, A Hosseinzade, M Salehi, P Merikhian, ... Journal of Pharmacy and Pharmacology 70 (7), 841-854, 2018 | 39 | 2018 |
| Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling F Khodabakhsh, P Merikhian, MR Eisavand, L Farahmand Cancer Cell International 21 (1), 200, 2021 | 32 | 2021 |
| MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy A Hosseinzadeh, P Merikhian, N Naseri, MR Eisavand, L Farahmand Cancer Cell International 22 (1), 110, 2022 | 20 | 2022 |
| Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk K Barzaman, R Vafaei, M Samadi, MH Kazemi, A Hosseinzadeh, ... Cancer Cell International 22 (1), 259, 2022 | 17 | 2022 |
| Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors P Merikhian, B Darvishi, N Jalili, MR Esmailinejad, AS Khatibi, ... Molecular oncology 16 (2), 485-507, 2022 | 13 | 2022 |
